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Abstract
Background: In trials designed to estimate rates of perinatal mother to child transmission of HIV,
HIV assays are scheduled at multiple points in time. Still, infection status for some infants at some
time points may be unknown, particularly when interim analyses are conducted.
Methods:  Logistic regression models are commonly used to estimate covariate-adjusted
transmission rates, but their methods for handling missing data may be inadequate. Here we
propose using coarsened multinomial regression models to estimate cumulative and conditional
rates of HIV transmission. Through simulation, we compare the proposed models to standard
logistic models in terms of bias, mean squared error, coverage probability, and power. We consider
a range of treatment effect and visit process scenarios, while including imperfect sensitivity of the
assay and contamination of the endpoint due to early breastfeeding transmission. We illustrate the
approach through analysis of data from a clinical trial designed to prevent perinatal transmission.
Results: The proposed cumulative and conditional models performed well when compared to
their logistic counterparts. Performance of the proposed cumulative model was particularly strong
under scenarios where treatment was assumed to increase the risk of in utero transmission but
decrease the risk of intrapartum and overall perinatal transmission and under scenarios designed
to represent interim analyses. Power to estimate intrapartum and perinatal transmission was
consistently higher for the proposed models.
Conclusion: Coarsened multinomial regression models are preferred to standard logistic models
for estimation of perinatal mother to child transmission of HIV, particularly when assays are missing
or occur off-schedule for some infants.
Background
In trials designed to evaluate the efficacy of an interven-
tion to prevent perinatal mother to child transmission
(PMTCT) of human immunodeficiency virus (HIV),
infants are usually tested within 48 hours after birth, with
a second visit scheduled 4 to 8 weeks after birth, to deter-
mine their HIV status. Test results from these two visit
windows are used to ascertain the three main outcomes of
scientific interest:
A1 The probability of in utero transmission, estimated by
the fraction of infants testing positive at birth;
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A2 The probability of perinatal transmission, estimated by
the fraction of infants testing positive by 8 weeks;
A3 The probability of intrapartum transmission, esti-
mated by the fraction of infants testing positive by 8 weeks
who tested negative at birth.
Subsequent visits may take place (i.e., after 8 weeks) but
tests at these visits only contribute information about the
outcomes of interest if the infant has missed earlier sched-
uled visits.
In primary analyses, we are usually interested in obtaining
unadjusted estimates of A1, A2, and A3. In secondary
analyses, covariate-adjusted estimates are often desired. If
every infant was tested in every visit window, we could use
a binary endpoint approach such as logistic regression to
obtain adjusted estimates for each of the three main out-
comes. However, missed and off-schedule visits are not
uncommon in PMTCT trials. And, even if there are no
missed visits, interim analyses may occur when only a
fraction of the infants are old enough for the second visit.
Table 1 lists a selection of primary papers from trials
aimed at reducing PMTCT of HIV and summarizes their
methods for unadjusted and adjusted analysis. These
methods are among the more commonly used for estimat-
ing PMTCT of HIV. In adjusted analyses, the endpoint is
generally modeled as either binary or right-censored con-
tinuous using logistic or Cox proportional hazards (PH)
regression, respectively. For both logistic and Cox PH
models, methods currently used for handling missing
data may be inadequate. For example, when the logistic
model is used and a test result is missing for an infant who
has not previously tested positive, the observation is
dropped, although if subsequent tests are negative, the
missing test result may be imputed to be negative. When
the Cox PH model is used, an infant's time to HIV infec-
tion is right censored at his or her last negative test; how-
ever, approaches for addressing timing of infection when
a missing visit is followed by a positive test and there have
been no previous positive tests may be inadequate. Some
authors use the time of the first positive test as the time of
infection while others use the midpoint between the last
negative and first positive tests (or birth and the first pos-
itive test). Cox PH models do not specifically address
treatment effects on A1–A3 but instead estimate the aver-
age treatment effect over the observation period. While we
generally think of using Cox PH models to model time to
an event, in the case of PMTCT, the event of interest has
already occurred (or not occurred) when an infant is first
tested. Because of the imperfect sensitivity of the test,
however, we may not have been able to detect it.
We propose a coarsened multinomial regression model
for analyzing PMTCT of HIV that accommodates missing
and off-schedule test data and allows the effect of treat-
ment to depend upon time. The approach is motivated by
the HIV Prevention Trials Network (HPTN) 024 study, a
multi-site placebo-controlled trial of antiobiotics to pre-
vent chorioamnionitis and, therefore, PMTCT of HIV. In
HPTN 024, of the 2,052 liveborn infants, 1,813 (88%)
had HIV tests within 48 hours of delivery and 1,696
(83%) had tests 4 to 8 weeks after delivery. Only 1,584
(77%) had tests both within 48 hours of delivery and 4 to
8 weeks after delivery. While missed visits were sometimes
due to the infant's death, in some cases the mother simply
forgot or was unable to bring the infant in for follow-up.
Many mothers did not deliver at the study hospital and
had to bring their infants in later for the birth HIV test,
resulting in visits that occurred off schedule.
Bertolli et al. [1] use a coarsened data approach to esti-
mate unadjusted rates of in utero and intrapartum trans-
mission based on the assumption that infants with
missing test data are distributed among transmission
groups in the same proportions as infants with non-miss-
ing test data. Magder et al. [2] expand on this approach,
using logistic regression to estimate covariate-adjusted
associations between various risk factors and presumed
time of transmission, while allowing for misclassification.
Little and Rubin [[3], pp. 169–70] describe an approach
Table 1: Approaches taken in selected papers analyzing PMTCT of HIV.
Unadjusted Adjusted Censoring
Wiktor et al. [4] KM1 - at last negative test
Guay et al. [16] KM PH2 at last negative test
Dabis et al. [17] KM PH not stated
Shaffer et al. [6] KM logistic regression not stated
Kuhn et al. [18] KM PH and logistic regression at last follow-up
Fawzi et al. [19] Chi-square tests PH not stated
Dorenbaum et al. [7] Fisher's exact tests logistic regression -
Moodley et al. [8] KM PH and logistic regression at last follow-up
Magder et al. [2] likelihood approach logistic regression (coarsened data) -
1Kaplan-Meier. 2Cox proportional hazards.BMC Medical Research Methodology 2008, 8:46 http://www.biomedcentral.com/1471-2288/8/46
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for estimating the parameters of a coarsened multinomial
model using the Expectation Maximization algorithm.
While it addresses the problem of incomplete data, it does
so only for a single sample or independent samples. Here
we allow for regression models of the probabilities for the
three outcomes of interest. We begin by describing the
coarsened multinomial model then lay out strategies to
adjust for covariates. Next, we describe a simulation study
designed to evaluate the performance of the proposed
regression estimators and compare them to more com-
monly used approaches in PMTCT trials. We illustrate our
approach with an analysis of HPTN 024 study data then
follow with discussion and conclusions.
Methods
The coarsened multinomial model
In this section, we present the coarsened multinomial
model. In this general presentation, we assume that there
are J visit windows. Usually, when estimating PMTCT, J =
2, corresponding to birth and 4 to 8 weeks. However,
depending upon the study design, J may be larger as in
Wiktor et al. [4], where the main endpoint was infection
status at three months, and infants were tested at birth,
four weeks, and three months.
We begin by dividing the follow-up time into windows as
follows:
Here tj1 and tj2 indicate the times at which the jth visit win-
dow starts and ends, respectively. These intervals do not
have to be and usually are not contiguous. In other words,
tj2 is not necessarily equal to tj+1,1. Unscheduled or off-
schedule visits result in tests that occur in the interval [tj2,
tj+1,1).
We define a complete response vector for the ith, i = 1,...,
N, infant as  , where   = 1, j = 1,..., J
+ 1, if the infant tests positive for the first time at the jth
visit and 0 otherwise. The vector   represents a multino-
mial response as the ith infant can only test positive for
HIV for the first time once. When an infant misses a sched-
uled visit (including if he or she is late or early for the
visit), we observe a coarsened version of  , which we
denote Yi = (Yi1,..., Yi,J+1)'. Effectively, Yij = 1 for all the win-
dows in which the infant may have first become positive.
More formally, taking   and   to be the time of the first
positive test result for infant i and the time of the last neg-
ative test result for infant i, respectively, we define Yi as
For infants with no positive test result during follow-up,
we take   = ∞. For infants with no negative test result
during follow-up, we take   = -∞. We assume that each
infant has at least one (non-missing) test result during the
follow-up period.
To illustrate how the observed vector Y  relates to the
unobserved but true outcome Y*, we look at two possible
visit and outcome patterns. First, we examine the effect of
a missed visit assuming J = 2 visit windows. We consider
infant  A, who was not tested until the second visit at
which point he or she tested positive. We do not know if
infant A would have tested positive had he or she come in
for the first visit. We can say, however, that the infant
would have tested positive for the first time at the first visit
or at the second visit if tested at both. In other words, Y*
for this infant may be (1, 0, 0)' or (0, 1, 0)' but is not (0,
0, 1)'. Therefore, by equations (1), (2), and (3), Y = (1, 1,
0)'. Next, we consider infant B who missed the first visit
and tested negative at the second visit. We assume that if
an infant tests negative at the end of the study he or she
was negative throughout the study; therefore, Y* = (0, 0,
1)' and Y = (0, 0, 1)' for this infant. In this case, even
though the infant was not tested in every visit window, we
have complete information regarding his or her outcome.
This illustrates one difficulty involving missed visits. If a
infant is uninfected and misses all visits except the last
(the Jth visit), we still have complete information about
him or her (as in B); however, if the infant is infected at
the last visit (as in A), we have incomplete information
about him or her.
Modeling cumulative rates of transmission
We begin by considering regressions on cumulative prob-
abilities in order to estimate endpoints A1 and A2, the in
utero and perinatal transmission rates. We define the
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probability that the ith infant's first positive test occurs in
the jth visit window as πij and the probability that the ith
infant's first positive test occurs after the last visit window
as  . To examine the relationship
between a set of predictors, (Xi1,..., Xim), and the probabil-
ity that infant i tests positive at or before the jth visit, we
define the following regression model:
where g(·) is a link function that specifies the relationship
between the predictors Xi  = (1, Xi1,...,  Xim)'  and the
response, through the parameter vector βj = (βj0,..., βjm)' of
length m+1. For ease of exposition, we assume that a pre-
dictor is relevant for all visit windows; however, this is not
necessary as will be illustrated in the HTPN 024 analysis.
When modeling cumulative rates or probabilities, two
appropriate choices for the link function are the log link,
where  g(p) = log(p), and the logit link, where g(p) =
logit(p) = log{p/(1 - p)}. When using the logit (log) link,
βjl, l = 1...,m, is interpreted as the log odds ratio (log rela-
tive risk) for testing positive at or before the jth visit win-
dow per one unit increase in Xil, l = 1,..., m.
We combine and re-write equations (4) and (5) to obtain
the following expressions for πij:
The log-likelihood, written in terms of the coarsened data,
is given by
and maximum likelihood methods are used to estimate
the parameters (see Maximum likelihood estimation of
parameters below).
Modeling conditional rates of transmission
We now consider regressions on conditional probabilities
to estimate endpoint A3, the intrapartum transmission
rate. To examine the relationship between a set of predic-
tors (Xi1,...,  Xim) and  , the condi-
tional transmission rate or probability of first testing
positive at the jth visit given a negative test result at the (j
- 1)th visit, we define the following regression model:
where g(·) is a link function that specifies the relationship
between the predictors Xi  = (1, Xi1,...,  Xim)'  and the
response, through the parameters vectors β1 = (β10,...,
β1m)'  and  , each of
length m + 1. When using the logit (log) link,  , l
= 1..., m, is interpreted as the log odds ratio (log relative
risk) for testing positive at the jth visit, given a negative
result at the (j - 1)th visit, per one unit increase in Xil, l =
1,..., m.
We calculate πij, j = 2,..., J, for use in the log-likelihood as
where
Equation (6) then provides the likelihood for the coars-
ened data.
Maximum likelihood estimation of parameters
To obtain maximum likelihood estimates of the regres-
sion parameters, we maximize equation (6) using numer-
ical optimization techniques. The optimization procedure
requires that πi1,...,  πiJ  lie between 0 and 1 and that
 be less than 1 for all i. If these constraints are not
met by the form of the regression models, we impose
them through the optimization procedure via non-linear
constraints on the coefficients. Further implications of the
constraints are presented in the discussion.
For the analyses presented here, numerical optimization
was carried out using a quasi-Newton algorithm. The
algorithm is an efficient modification of Powell's Variable
Metric Constrained WatchDog algorithm, which is availa-
ble in SAS PROC NLP [5]. Additional details regarding our
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implementation, including SAS macros for fitting the
cumulative and conditional models with the logit link for
an arbitrary number of visit windows, are available from
the authors upon request.
Simulation study
We performed simulations to assess the properties of the
proposed regression estimators and compare them to
more commonly used regression approaches. We consid-
ered the case of two visit windows corresponding to birth
and 4 to 8 weeks. For each simulated data set, we ran-
domly generated covariates that informed the infant's
simulated mode of transmission (in utero, during deliv-
ery, or neither). We allowed for imperfect sensitivity of the
assay shortly after transmission by simulating time of
detectable infection and allowed the simulations to reflect
additional positive test results at the 4 to 8 week visit due
to breastfeeding. We randomly generated a set of visit
times for each infant, independent of covariates but
dependent upon the endpoint, with infants having simu-
lated time of detectable infection equal to 0 days slightly
more likely to attend the 4 to 8 week visit. We determined
each infant's observed endpoints by comparing his or her
simulated time of detectable infection to his or her simu-
lated visit times. Additional details regarding the simula-
tion of time of detectable infection and visit process are
provided in Appendices A and B (Additional files 1 and
2), respectively.
We fit the cumulative and conditional regression models
using standard logistic regression and the proposed coars-
ened multinomial (CM) regression models with the logit
link. We considered two sets of logistic models: the first
(L-CUM) modeled infection at birth and infection at 4 to
8 weeks, and the second (L-COND) modeled infection at
birth and infection at 4 to 8 weeks among infants known
to be HIV negative at birth. The logistic models considered
all infants for whom HIV status at birth and HIV status at
4 to 8 weeks could be determined and were chosen to rep-
resent those commonly used in the analysis of PMTCT of
HIV [6-8]. Cox PH models, although also used, do not
specifically address treatment effects on A1–A3 but
instead estimate the average effect of treatment over the
observation period; therefore, we did not assess them in
our simulations. We compared the effects of treatment as
obtained from the regression models to the true effects of
treatment according to which the data were generated,
determining bias, mean squared error (MSE), 95 percent
coverage probability (CP), and power for each estimator.
We considered several scenarios, allowing for different
treatment effects (TEs) and different visit processes (VPs)
that resulted in varying amounts of missing data. Results
are provided for each scenario based on 1000 data sets of
1500 observations each.
In carrying out numerical optimization, we chose the con-
vergence criteria for the proposed cumulative and condi-
tional regression models to coincide with the convergence
criteria for the logistic regression models in SAS PROC
LOGISTIC [9].
HPTN 024
To illustrate our approach, we analyzed data from HPTN
024, a multi-site double-blinded placebo controlled trial
of antiobiotics to prevent chorioamnionitis and, there-
fore, perinatal transmission of HIV. The trial enrolled
pregnant, HIV positive women receiving care in hospitals
and clinics in Malawi, Tanzania, and Zambia. Women
were randomized to receive either treatment or placebo.
Treatment consisted of two courses of antibiotics, with the
first course administered at enrollment (20 to 24 weeks
gestation) and the second at the onset of contractions
and/or premature rupture of membranes. All women and
their liveborn infants were offered single dose nevirapine
per World Health Organization recommendation [10].
Women were followed during their pregnancies, and their
infants were followed postnatally. Visit windows for
determining in utero and delivery/early postnatal trans-
mission in this breastfeeding population were 0 to 48
hours and 4 to 6 weeks, respectively. Because over half of
the visits scheduled to occur between 4 and 6 weeks actu-
ally took place between 6 and 8 weeks, we extended the
second visit window to 4 to 8 weeks for analysis purposes.
We also extended the birth visit window to 0 to 7 days.
At the first interim analysis, the NIAID Vaccine and Pre-
vention Data and Safety Monitoring Board reviewed trial
progress in a scheduled interim analysis and concluded
that, while statistical evidence neither established benefit
nor harm, the available evidence ruled out targetted levels
of benefit. They further recommended that HPTN 024
stop recruitment and administration of study drug and
continue follow-up of enrolled women and infants.
Administration of the study drug was halted on March 5,
2003. Additional details regarding the 024 study are pro-
vided by Taha et al. [11].
In this analysis, we examined the association between
PMTCT and antibiotics, comparing outcomes for infants
born to mothers randomized to antibiotics who delivered
prior to March 5, 2003 to infants born to mothers rand-
omized to placebo or to mothers randomized to antibiot-
ics who delivered after March 5, 2003. Additional
covariates of interest were log maternal viral load, mater-
nal CD4 count, and infant gender. In the birth model, we
adjusted for mother's use of nevirapine and, in the 4 to 8
week model, for mother's and infant's use of nevirapine.
To account for unmeasured differences between hospitals
and clinics, we included study site in both models.BMC Medical Research Methodology 2008, 8:46 http://www.biomedcentral.com/1471-2288/8/46
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Results
Simulation study
Table 2 provides simulation results for the six combina-
tions of treatment effect and visit process that we exam-
ined. These combinations illustrate the impact of
treatment effect on estimator performance for a given visit
process as well as the impact of visit process (i.e., varying
levels of missingness) on estimator performance for a
given treatment effect. Because we allowed for imperfect
sensitivity and early breastfeeding transmission, we would
not expect to see zero bias in the estimates from our sim-
ulations. Relative bias (not shown in table) of estimators
Table 2: Simulation results for six treatment effect (TE)/visit process (VP) scenarios.
Bias MSE CP Power
Scenario A1 A2/A3 A1 A2/A3 A1 A2/A3 A1 A2/A3
TE1/VP1 (β11 = -0.55, β21 =   β2|1-,1 = -0.54)
L-CUM 0.013 0.045 0.069 0.030 0.948 0.943 0.518 0.845
CM-CUM 0.027 0.048 0.068 0.027 0.948 0.939 0.499 0.882
L-COND -0.015 0.107 0.077 0.077 0.959 0.914 0.539 0.439
CM-COND -0.007 0.106 0.072 0.072 0.956 0.901 0.541 0.461
TE2/VP1 (β11 = -0.55, β21 = β2|1-,1  = 0)
L-CUM 0.173 -0.020 0.096 0.022 0.879 0.952 0.309
CM-CUM 0.168 -0.009 0.094 0.020 0.873 0.952 0.339
L-COND 0.098 0.004 0.083 0.050 0.938 0.956 0.398
CM-COND 0.101 0.006 0.079 0.046 0.941 0.952 0.405
TE3/VP1 (β11 = -0.02, β21 = β2|1-,1 = -0.38)
L-CUM -0.078 0.055 0.058 0.029 0.952 0.931 0.057 0.517
CM-CUM -0.064 0.049 0.054 0.025 0.954 0.933 0.056 0.605
L-COND -0.050 0.064 0.062 0.059 0.946 0.941 0.062 0.263
CM-COND -0.042 0.063 0.058 0.055 0.944 0.944 0.057 0.264
TE4/VP1 (β11 = 0.27, β21 = β2|1-,1 = 0.27)
L-CUM -0.123 0.059 0.065 0.028 0.921 0.936 0.096 0.271
CM-CUM -0.105 0.049 0.057 0.023 0.931 0.942 0.111 0.307
L-COND -0.043 0.034 0.058 0.060 0.953 0.937 0.160 0.173
CM-COND -0.038 0.033 0.055 0.056 0.954 0.936 0.186 0.187
TE4/VP2
L-CUM -0.110 0.116 0.064 0.045 0.927 0.898 0.103 0.138
CM-CUM -0.096 0.043 0.059 0.032 0.927 0.940 0.128 0.261
L-COND -0.073 0.041 0.061 0.084 0.941 0.949 0.138 0.123
CM-COND -0.066 0.042 0.054 0.078 0.946 0.945 0.146 0.134
TE4/VP3
L-CUM -0.124 0.192 0.113 0.105 0.923 0.890 0.068 0.064
CM-CUM -0.088 0.017 0.097 0.058 0.939 0.954 0.096 0.193
L-COND -0.054 -0.009 0.099 0.292 0.944 0.967 0.095 0.077
CM-COND -0.040 0.002 0.087 0.211 0.946 0.964 0.102 0.086
TE scenarios are defined by β11, β21, and β2|1-,1, which represent the true log odds ratios for in utero transmission (A1), perinatal transmission (A2), 
and intrapartum transmission (A3), respectively, comparing treatment versus control (see Appendix A). VP scenarios are defined such that the 
amount of missing data increases from VP1 to VP3 (see Appendix B). L-CUM = logistic model, cumulative probabilities; CM-CUM = coarsened 
multinomial model, cumulative probabilities; L-COND = logistic model, conditional probabilities; CM-COND = coarsened multinomial model, 
conditional probabilities. Results for estimators of treatment effect on perinatal transmission and intrapartum transmission are combined under the 
heading A2/A3.BMC Medical Research Methodology 2008, 8:46 http://www.biomedcentral.com/1471-2288/8/46
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of treatment effect on perinatal and intrapartum transmis-
sion ranged from 0.007 (conditional CM model) to 0.711
(cumulative logistic model), corresponding to the sce-
nario where treatment was assumed to increase the risk of
in utero transmission but decrease the risk of intrapartum
and overall perinatal transmission (TE4) and the visit
process resulted in the most missing data (VP3).
Cumulative regression models
The proposed cumulative regression model (CM-CUM)
performed comparably to, or better than, the logistic
regression model (L-CUM) across all performance meas-
ures for all scenarios except where treatment was assumed
to reduce the odds of in utero and intrapartum transmis-
sion by roughly equal amounts (TE1) and the visit process
resulted in the least amount of missing data (VP1). For
this scenario, the birth estimate was less biased in the
logistic model.
The CM model performed most impressively for the TE4
scenarios. As the amount of missing test result data
increased (from VP1 to VP3), the improvement offered by
the CM model increased. Specifically, considering 4 to 8
weeks, the bias for the logistic model increased from 1.2-
fold over the CM model under VP1 to 2.7- and 11.3-fold
under VP2 and VP3, respectively.
Across all scenarios, MSE was consistently lower (albeit
only slightly in most cases) for the CM model than for its
logistic counterpart. The CPs for the competing cumula-
tive models were similar while power at 4 to 8 weeks was
higher for the CM model for all scenarios where power
was assessed. The higher power observed at 4 to 8 weeks
compared to birth is not surprising given the smaller
probability of infection at birth.
Conditional regression models
On the whole, the proposed conditional regression model
(CM-COND) performed comparably to its logistic coun-
terpart (L-COND), with the CM model having less bias at
birth for all scenarios where a positive effect of treatment
on intrapartum and overall perinatal transmission was
assumed (TE1, TE3, and TE4). MSE was consistently
lower, although only slightly, for the CM model. While
power tended to be low for the conditional models, power
at birth and at 4 to 8 weeks was slightly higher for the CM
model for the TE4 scenarios.
HPTN 024
Of 2,052 firstborn infants born alive to HIV positive
mothers, 1,758 had complete data with respect to the cov-
ariates of interest. Of these, 1,696 had a test result at some
point during follow-up and were included in the analysis
of HIV infection. 1,739 had a test result or are known to
have died during follow-up and were, thus, included in
the analysis of HIV infection or death. Descriptive statis-
tics for the 1,739 infants included in the analysis of HIV
infection or death are provided in Table 3. Figure 1 pro-
vides the complete testing profile for the 1,758 infants
with complete covariate data, according to treatment
group.
We used the proposed regression methods to analyze the
outcomes infection and infection or death. We estimated
the odds of perinatal transmission using the proposed
cumulative model and the odds of in utero and intrapar-
tum transmission using the proposed conditional model.
Results are provided in Table 4. We found that treatment
was not significantly associated with a reduction in any of
the modes of PMTCT. These findings are consistent with
the intent-to-treat analysis as is the trend in the estimates
suggesting that treatment decreases the odds of in utero
transmission while increasing the odds of perinatal trans-
mission [11]. When we defined first positive test or death
at or before a given visit as the endpoint, we observed the
same trend, although slightly weaker.
Discussion
Many statistical techniques are available for estimating
PMTCT of HIV while adjusting for covariates. Among the
more commonly used are logistic regression models and
Cox proportional hazards models. While these methods
are relatively straightforward to implement, they do not
easily accommodate missed or unscheduled visits while
allowing for a time-varying treatment effect. Cox models
can be modified to allow the effect of treatment to depend
upon time but do not fully solve the problem of how to
handle missed or unscheduled visits. Interval censored
models, which use an infant's time to last negative test
and time to first positive test to form an interval around
his or her (unknown) time of infection, may better
accommodate the missing data, but software is not gener-
ally available for regression with interval censored data
unless we are willing to make parametric assumptions
about the distribution of the event times.
Recently, Bang and Spiegelman [12] proposed a likeli-
hood approach for a dichotomous outcome to estimate
Table 3: Descriptive statistics for 1,739 infants included in 
analysis of HIV infection or death.
Covariate Treatment Control
Mean/N SD/% Mean/N SD/%
Maternal viral load (1 log10 unit) 4.338 0.836 4.242 0.817
CD4 count (100 units) 3.697 2.067 3.796 2.234
Female infant 296 47% 566 51%
Mother nevirapine 603 95% 1066 96%
Mother and infant nevirapine 558 88% 1001 90%BMC Medical Research Methodology 2008, 8:46 http://www.biomedcentral.com/1471-2288/8/46
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mother to child transmission when infection status is
missing for some infants due to fetal loss. However, this
approach does not address all three of our endpoints of
interest or missing data due to incomplete follow-up.
Balasubramanian and Lagakos [13] provide methods for
estimating the continuous distribution of the timing of in
utero and peripartum transmission that account for the
imperfect sensitivity of the HIV assay. The authors devel-
oped the approach for settings in which there is no risk for
infection following birth and, therefore, do not address
the potential impact of breastfeeding.
We propose a coarsened multinomial approach for esti-
mating PMTCT that accommodates missing test result
data, regression on the three outcomes of interest, and
time-varying treatment effects. Through simulation, we
investigated the performance of the estimators obtained
from the more commonly used logistic regression
approaches and compared them to the proposed estima-
tors, including imperfect sensitivity of the assay and con-
tamination of the endpoint due to early breastfeeding
transmission. We found that both the proposed cumula-
tive model and the proposed conditional model per-
formed well when compared to their logistic counterparts.
Performance of the proposed cumulative model was par-
ticularly strong under scenarios where treatment was
assumed to increase the risk of in utero transmission but
decrease the risk of intrapartum and overall perinatal
transmission and under scenarios designed to represent
interim analyses. Power for the proposed models was con-
sistently higher at 4 to 8 weeks, which is to be expected
given that the logistic models used only data for infants
whose endpoints were non-missing or could be imputed
based on subsequent negative tests.
The coarsened multinomial regression approach is not
without limitations. Both the proposed cumulative and
conditional models impose non-linear constraints on the
coefficients, which can complicate interpretation of the
estimates if maximization of the likelihood occurs on the
boundary of the parameter space. In the case of the condi-
tional model, however, only a single constraint is
imposed, which is no more than would be imposed for a
general multinomial model [[14], p. 21]. In numerous
simulations (beyond those presented here), we saw no
evidence of bias due to maximization on the boundary.
HPTN 024 testing profile Figure 1
HPTN 024 testing profile.
1758 firstborn, liveborn, with 
HIV infected mother 
(all covariates non-missing)
641 treatment
64 no specimen at birth
19 died prior to birth visit
28 no specimen at 4-8 weeks
17 specimen at 4-8 weeks
577 specimen 
at birth
77 no specimen at 4-8 weeks
500 specimen at 
4-8 weeks
7 died prior to 
4-8 week visit
1117 control
94 no specimen at birth
20 died prior to birth visit
29 no specimen at 4-8 weeks 
(includes 3 deaths between birth 
and 4-8 week visit)
45 specimen at 4-8 weeks 1023 specimen 
at birth
140 no specimen at 4-8 weeks
883 specimen at 
4-8 weeks
16 died prior to 
4-8 week visitBMC Medical Research Methodology 2008, 8:46 http://www.biomedcentral.com/1471-2288/8/46
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Our approach relies on the assumption that missingness
is non-informative and, thus, may be more appropriate
for some endpoints (infection/death) than for others
(infection). While the model can be used in a breastfeed-
ing population, it does not allow us to separate intrapar-
tum transmission from early transmission due to
breastfeeding.
While we have attempted to assess the impact of misclas-
sification in our simulations, our approach uses probabil-
ities of first testing positive to estimate transmission
probabilities and, in doing so, does not formally account
for misclassification due to the imperfect sensitivity of
testing. A possible extension of this approach would
involve introduction of a latent variable representing an
infant's true infection status. One could link an infant's
probability of infection at a given time point to his or her
coarsened test result via his or her complete (unobserved)
test result and, in doing so, incorporate information
about the sensitivity of testing in the manner of Magder
and Hughes [15]. Given the multivariate nature of the
outcome and missingness in the test result, such an exten-
sion would introduce considerable complexity.
Conclusion
Here we have studied the problem of estimating the effect
of treatment on PMTCT of HIV when outcome data are
incomplete. We describe methods that give consistent and
asymptotically normal estimators using maximum likeli-
hood theory. Through simulation, we have shown that
the proposed models outperform standard logistic mod-
els in terms of bias, mean squared error, coverage proba-
bility, and power under a range of treatment effect and
visit process scenarios designed to reflect a PMTCT setting.
Given their strong performance, coarsened multinomial
regression models are to be preferred to standard logistic
models for estimation of perinatal mother to child trans-
mission of HIV, particularly when assays are missing or
occur off-schedule for some infants.
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Table 4: Adjusted odds ratios at birth, 4 to 8 weeks.
Risk factor In utero Perinatal Intrapartum
OR 95% CI OR 95% CI OR 95% CI
Infection endpoint (612 treatment, 1084 control)
Treatment vs. control 0.691 0.469, 1.017 0.987 0.736, 1.323 1.404 0.928, 2.123
Maternal viral load (1 log10 unit) 2.552 1.895, 3.437 2.820 2.221, 3.579 2.873 2.023, 4.082
CD4 count (100 units) 1.037 0.939, 1.145 1.099 1.015, 1.190 1.172 1.033, 1.331
Female infant 0.938 0.658, 1.339 1.011 0.764, 1.338 1.101 0.733, 1.654
Mother nevirapine 0.549 0.248, 1.215
Mother and infant nevirapine 0.628 0.387, 1.019 0.562 0.262, 1.206
Infection/death endpoint (632 treatment, 1107 control)
Treatment vs. control 0.873 0.632, 1.205 1.025 0.789, 1.332 1.245 0.850, 1.825
Maternal viral load (1 log10 unit) 2.299 1.786, 2.959 2.568 2.086, 3.161 2.597 1.895, 3.558
CD4 count (100 units) 1.043 0.959, 1.135 1.098 1.024, 1.178 1.175 1.048, 1.318
Female infant 0.883 0.650, 1.201 1.066 0.829, 1.370 1.336 0.916, 1.949
Mother nevirapine 0.221 0.128, 0.381
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